Vir Biotechnology (VIR) Stock: Buy, Sell, or Hold?
VIR - Vir Biotechnology, Inc. Common Stock
$10.62
0.04 (0.38%)
â˛
5d:
-7.25%
30d:
+18.53%
90d:
+24.65%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When VIR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: VIR is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: VIR is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: VIR is currently trading at $10.62, which is considered slightly high relative to its 30-day fair value range of $9.05 to $11.04.
Technical Outlook: Technically, VIR is in a downtrend. The price is currently testing key support at $10.38. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: VIR scores 31/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $20.78 (+95.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VIR is in a downtrend. The price is currently testing key support at $10.38. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: VIR scores 31/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $20.78 (+95.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$9.05 -
$11.04
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
42.1%
All Signals
- BEARISH: Weak technical setup (31/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 95.6% below Wall St target ($20.78)
- WARNING: Composite score 44/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$9.05 -
$11.04
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$10.38
Resistance Level
$11.94
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.27
Wall Street Target
$20.78
(+95.6%)
Revenue Growth (YoY)
19582.5%
Earnings Growth (YoY)
58.5%
Profit Margin
-83.0%
Share & Embed Analysis
Last updated: September 13, 2026 4:11 AM ET
Data refreshes hourly during market hours. Next update: 5:11 AM
Data refreshes hourly during market hours. Next update: 5:11 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VIR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Backer Marianne De
SELL
72559 shares
2026-04-06
Vicki L Sato
SELL
22000 shares
2026-04-01
Brent Sabatini
SELL
7711 shares
2026-03-23
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 52 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$88 | 50 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 49 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$9 | 41 HOLD |
